TABLE 1.
Strains and plasmids used in this study
| Strain or plasmid | Relevant characteristicsa | Source or reference |
|---|---|---|
| E. coli strains | ||
| DH5α | Δ(lacZYA-argF)U169 hsdR17 relA1 supE44 endA1 recA1 thi gyrA96 φ80dlacZΔM15 | Life Technologies, Gaithersburg, Md. |
| JM109 | endA1 recA1 gyrA96 thi hsdR17 relA1 supE44 Δ(lac-proAB) mcrA [F′ traD36 proAB+ lacIqZΔM15] | 65 |
| JM109(DE3) | endA1 recA1 gyrA96 thi hsdR17 relA1 supE44 Δ(lac-proAB) mcrA [F′ traD36 proAB+ lacIqZΔM15] λ(DE3) | Promega Corp. |
| ES1301 mutS | KmrlacZ53 mutS201::Tn5 thyA36 rha-5 metB1 deoC IN(rrnD-rrnE) | Promega Corp. |
| Plasmids | ||
| pDTG141 | Apr; nahAaAbAcAd (encoding the naphthalene dioxygenase components reductaseNAP, ferredoxinNAP, and large and small subunits of the oxygenase, respectively) under the control of the T7 promoter of pT7-5 | 61 |
| pMASTER-1 | Tcr Aps; pALTER-1 carrying the KpnI-XbaI fragment of pDTG141 (nahAc′Ad) | 50 |
a
Kmr, kanamycin resistance; Apr, ampicillin resistance; Tcr, tetracycline resistance.